On February 23, 2010
J&J’s Dilemma: Marketing New Drugs Without Cannibalizing Its Lead Product
Remicade (infliximab), a biologic approved for the treatment of rheumatoid arthritis and other autoimmune diseases, remains the top growth driver for Johnson & Johnson (JNJ). Positioning two new biological entrants approved in 2009 for similar commercial successes will be challenging,
…
0 Comments